Current Issues on Denosumab Use in Giant Cell Tumor of Bone
Open Access
- 1 January 2023
- journal article
- Published by XMLink in Journal of the Korean Orthopaedic Association
- Vol. 58 (6) , 485-490
Abstract
주민욱, et al. J Korean Orthop Assoc. 2023 Dec;58(6):485-490. https://doi.org/10.4055/jkoa.2023.58.6.485Keywords
This publication has 50 references indexed in Scilit:
- Risk Factors for Pulmonary Metastases from Giant Cell Tumor of BoneJournal of Bone and Joint Surgery, 2015
- A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant DenosumabJournal of Bone and Joint Surgery, 2014
- Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II studyActa Oncologica, 2014
- Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic TargetsPediatric Drugs, 2013
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF IIBone, 2011
- Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 studyThe Lancet Oncology, 2010
- Osteoprotegerin Reduces the Serum Level of Receptor Activator of NF-κB Ligand Derived from OsteoblastsThe Journal of Immunology, 2007
- Histologically verified lung metastases in benign giant cell tumours—14 cases from a single institutionInternational Orthopaedics, 2006
- Malignancy in giant cell tumor of boneCancer, 2003